Progress in feline diabetes: keys to achieve diabetic remission by Reusch, C E
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Progress in feline diabetes: keys to achieve diabetic remission
Reusch, C E
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-127483
Originally published at:
Reusch, C E (2016). Progress in feline diabetes: keys to achieve diabetic remission. In: Congresso
International Novotech Veterinaria, Madrid, Spain, 21 May 2016 - 21 May 2016.
Progress in feline diabetes: keys to achieve diabetic remission 
Prof. Dr. Claudia E. Reusch, Dipl ECVIM-CA 
Clinic for Small Animal Internal Medicine, University of Zurich, Switzerland 
 
Remission of diabetes is defined as a situation in which clinical signs of diabetes disappear, blood 
glucose concentration normalizes and insulin treatment can be discontinued. In human medicine, the 
duration of normoglycemia has to be at least one year to be labelled remission (Buse et al, 2009). In 
cats, there is not yet an agreement of the time period. In Zurich we use a cut-off of 4 weeks as 
criterion, i.e. the disease-free interval has to last for a minimum of 4 weeks before the diabetes is 
considered to be in remission (Sieber-Ruckstuhl et al, 2008; Zini et al, 2010; Tschuor et al, 2011; 
Hafner et al, 2014; Zini et al, 2015).  The first study on cats which had experienced diabetic remission 
was published by Nelson et al in 1999, at that time the phenomenon was called “transient diabetes”. 
Interestingly, at the time of diagnosis of the diabetes in those cats, baseline insulin concentrations 
were undetectably low or within the reference range and did not increase after IV glucagon 
administration, mimicking type 1 diabetes. A second glucagon test, performed after remission had 
occurred, showed an immediate and significant increase in insulin concentration similar to test 
results in healthy cats. Histological evaluation of the pancreas revealed decreased numbers of islets, 
islet amyloidosis and vacuolar degeneration of islet cells. This study demonstrates that initial insulin 
secretion is severely impaired even in cats with the potential of remission, and that the glucagon test 
performed at the time of diagnosis is not helpful to predict remission.  The study also showed, that 
cats experiencing diabetic remission are not “cured”, as they have islet cell pathology. The vast 
majority of cats in diabetic remission has impaired glucose tolerance and severe impairment of 
glucose tolerance is associated with relapse of diabetes (Gottlieb et al 2015). Remission is 
increasingly recognized and it is well accepted that good glycemic control improves β-cell function 
leading to diabetic remission in a substantial percentage of cats. Treatment may lead to 
improvement of β-cell function, most likely due to abolishment of the damaging effects of high blood 
glucose on β-cell function (glucotoxicity). Those cats most likely have a type 2 like diabetes resulting 
from insulin resistance and β-cell dysfunction and some degree of β-cell loss. Their remaining β-cells, 
however, have the capacity to recover, at least in part, during treatment. Cats which do not 
experience diabetic remission may be in a more advanced stage of their disease with more 
pronounced β-cell loss. Alternatively, those cats may suffer from concurrent disease, for instance 
chronic renal failure or pancreatitis, which renders glycemic control difficult and may make remission 
impossible. In 10 – 15% of diabetic cats the disease is caused by hypersomatotropism (acromegaly) 
and in those cases, remission is unlikely.  Diabetic remission most often occurs during the first three 
to four months of therapy. Consequently, the first months after diagnosis is the most important time 
during management of diabetes in cats and therapy should be started without delay. Remission rate 
is low when oral hypoglycemic agents (i.e. glipizide) are used as the sole agent and therefore,  insulin 
is the preferred medical therapy with the highest chance of diabetic remission. It is currently believed 
that remission rates are higher when cats are treated with newer types of insulin (e.g. insulin 
analogues such as glargine or determir) than with older types of insulin (e.g. lente type) (Marshall et 
al, 2009; Roomp and Rand, 2009; Roomp and Rand, 2012). For instance in two recent studies, using 
insulin glargine and determir respectively, overall remission rates of 64% and 67% were achieved 
(Roomp and Rand, 2009; Roomp and Rand, 2012). Those studies, however, used an extremely 
intensive treatment and monitoring protocol: glucose targets were set very low (50 – 200 mg/dl and 
50 – 100 mg/dl respectively; 2.8 – 11.1 mmol/l, 2.8 – 5.5. mmol/l), the owners had to measure blood 
glucose at home at least three times daily and adapt the insulin dosage accordingly. Another study 
found that in cats in which insulin dosing was based on maintaining blood glucose between 60 and 
160 mg/dl (3.3 and 8.8 mmol/l), remission was seen significantly more often compared to cats in 
which insulin dosing was based on clinical signs (Nack and DeClue, 2014). Those treatment protocols 
can only be used under very close supervision, as there is an increasing risk of hypoglycaemia the 
lower the glucose targets are set. The overall reported remission rate in studies using insulin glargine 
(Lantus) is 47.6% (Gostelow et al,  2014). The AAHA diabetes management guidelines recommend to 
use insulin glargine (Lantus) or PZI (ProZinc) as initial insulins of choice (Rucinsky et al, 2010), the 
recent ISFM guidelines recommend the same two types of insulin as well as insulin detemir (Levemir) 
(Sparkes et al, 2015).  Although duration of action is quite long (> 12 hours) those three insulins 
should be injected twice daily for optimal glycemic control. Diet is an important component of the 
treatment plan. There is current agreement that a high-protein-low carbohydrate diet should be fed, 
the AAHA guidelines recommend to feed a diet with the lowest carbohydrate content the cat will eat. 
Wet food is preferred over dry food as it provides lower carbohydrate levels, lower energy density 
and additional water intake. In case of obesity, calories should be restricted to achieve 1- 2% weight 
loss per week (Rucinsky et al, 2010). According to Bennet et al (2006) remission rate is higher in cats 
fed a low-carbohydrate diet compared to cats fed a diet with moderate carbohydrate content.  
As shown by Nelson et al (1999), no difference in insulin response during glucagon test was seen in 
cats with and without remission. Studies in humans have demonstrated that the first defect in the 
early phase of diabetes is a loss response to IV glucose, followed by a loss of response to IV glucagon, 
whereas response to arginine persists the longest. It was, therefore, hypothesized that cats, which 
experience remission at some time after starting treatment, have less severe β-cell defects than cats 
with permanent disease and would therefore show normal or at least some degree of insulin 
response after IV arginine. However, the expectations were not met. In both groups of cats 
(remission and no remission) insulin concentrations increased mildly after IV arginine, but there was 
no significant difference between the two groups, similar to what has been shown with the glucagon 
test  (Tschuor et al, 2011).  Therefore, none of the tests used so far allows discrimination between 
cats with and without the chance of remission. Long duration of diabetes, presence of diabetic 
polyneuropathy, hypercholesterolemia and clearly increased fPLi seem to be associated with a lower 
chance of diabetic remission (Roomp and Rand, 2009; Zini et al, 2015). In contrast, cats which 
developed the diabetes after glucocorticoid therapy have a good chance to experience remission. In 
one of our studies we found that remission was more likely with older age (Zini et al, 2010). 
Interestingly, diabetic ketoacidosis has not been identified as a negative predictive factor and 
remission may also occur in cats presented with diabetic ketoacidosis (Sieber-Ruckstuhl et al, 2008). 
In many cats, remission lasts for months to years and may even be life-long. Roughly 30% of cats with 
remission will have a relapse with recurrence of clinical signs and hyperglycemia and will again 
require insulin therapy. In some of them, a second remission is possible, more often, however, 
permanent insulin therapy is required.  
In our own institution remission rate has varied between 40 and 50% over the years under the 
following conditions: cats are newly diagnosed with diabetes and have no severe concurrent diseases 
(e.g. heart failure, renal failure, severe pancreatitis, hypersomatotropism), they are treated according 
to a standardized insulin treatment protocol, fed a low-carbohydrate-high-protein diet and are 
frequently re-evaluated during the first 4 months of therapy. We do not follow an aggressive 
remission protocol, because our primary aim is to control clinical signs of diabetes and to avoid 
hypoglycaemia. Our insulins of first choice are insulin glargine (Lantus) or PZI (ProZinc). In cats < 4 kg 
body weight starting dose of insulin glargine usually is 1 U/cat BID, in cats > 4 kg 1.5 U/cat. When PZI 
is used starting doses usually are 0.5 U/cat higher (1.5 U/cat and 2 U/cat).   A high-protein-low-
carbohydrate diet (Purina DM) is highly recommended to all owners. During the initial visit a 
thorough work-up is performed including routine laboratory evaluation and abdominal 
ultrasonography and concurrent disease are treated whenever possible. As a minimum, re-
evaluations are scheduled after 1, 2, 6, 10 and 16 weeks, some cats need additional appointments. 
Re-evaluations include a thorough history, physical examination, generation of a blood glucose curve 
(measurement of blood glucose every 2 hours) and measurement of fructosamine. The owners are 
introduced to home-monitoring of blood glucose after 1 – 2 weeks. Home-monitoring allows more 
frequent blood glucose measurements and more frequent amendments of the insulin dose. 
Additionally, measurements are not influenced by the stress of hospitalisation. For the initial 
treatment period (first 3 to 4 months) we recommend that owners measure the fasting blood 
glucose at least twice per week and generate a blood glucose curve once per week (e.g. on Sundays). 
The highest blood glucose should not exceed 10 and 15 mmol/ (180 - 270 mg/dl) and the glucose 
nadir should be between 4.5 and 7.8 mmol/l (80 and 140 mg/dl). When blood glucose curves are 
generated at home we aim for the lower glucose target (i.e. 10 mmol/180 mg/dl and 4.5 mmol/l/80 
mg/dl), when the curves are generated in the hospital we allow the higher end of the glucose targets. 
Dose titration is done in steps of 0.5 U/cat every 5 to 7 days, except in case of hypoglycemia where a 
more pronounced and more frequent dose reduction may be necessary. A blood glucose curve 
should be generated before each dose change. Some investigators advertise a more aggressive 
treatment protocol with lower glycemic targets, in particular a lower glucose nadir (see above). The 
most recent ISFM guidelines, however, recommend to avoid a glucose nadir < 4.5 mmol/l (80 mg/dl). 
If the glucose nadir is in the desired range, but duration of insulin effect is less than 8 – 10 hours, the 
cat should be switched to a longer acting insulin (e.g. switch from insulin glargine to insulin detemir 
or PZI).  
In cats, in which all blood glucose measurements of a blood glucose curve range between 4.5 – 6.7 
mmol/l (80 and 120 mg/dl) and fructosamine  is < 350 µmol/l, we start to reduce the insulin dose in 
steps of 0.5 U/cat BID every 5 – 7 days (Reusch, 2015). The owner is advised to monitor the cat 
closely with regard to re-appearance of clinical signs and a glucose curve is performed prior to each 
reduction step. The insulin is reduced until a dose of 0.5 U/cat BID is reached, thereafter,  the last 
step is to reduce insulin dose to 0.5 U/cat SID; if the blood glucose is still normal, insulin 
administration is stopped.  Close clinical monitoring and regular glucose measurement (e.g. fasting 
blood glucose twice per week) are recommended to ensure that there is no relapse of the disease. 
Most cats are well regulated or experience diabetic remission with insulin doses < 1. U/kg BID. The 
higher the insulin requirement, the more likely a concurrent disease is present causing insulin 
resistance. In those cases, further work-up should be pursued.   
In summary, important factors to increase the likelihood of diabetic remission are: 
early diagnosis,  immediate start of therapy with insulin glargine, insulin detemir or PZI, dietary 
management with a high-protein-low carbohydrate diet, close monitoring and adjustment of insulin 
dose based on clinical signs and blood glucose measurements.  
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